The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
Open accessAbstract
In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Cited by
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Metadata
- Authors
- Pizzorno, A., Padey, B., Dubois, J., Julien, T., Traversier, A., Dulière, V., Brun, P., Lina, B., Rosa-Calatrava, M., & Terrier, O.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 181
- Pages
- 104878
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W3043263509
- Cited by
- 159
- References
- 2
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. https://app.cochat.ai/papers/10.1016/j.antiviral.2020.104878
- The paper
- Pizzorno, A., Padey, B., Dubois, J., Julien, T., Traversier, A., Dulière, V., Brun, P., Lina, B., Rosa-Calatrava, M., & Terrier, O. (2020). In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research. https://doi.org/10.1016/j.antiviral.2020.104878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.